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 The Role of RASSF5 on Cell Growth and Hippo Signaling in Rhabdomyosarcoma 
Megan Garver, Dr. Lee Helman, MD* & Dr. Katrina Slemmons, PhD 
Introduction: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of 
childhood. Dysregulation of the Hippo pathway, a signaling cascade that regulates 
many biological processes, is associated with many human cancers. The goal of my 
project was to delete RASSF5, a regulator of the Hippo pathway, in RMS cells utilizing 
CRISPR/Cas9 and then to evaluate how the absence of RASSF5 affects RMS cell 
growth and Hippo signaling, with and without DNMTi Tx. 
Methods: A lipofectamine transfection was performed in two different RMS cell lines, 
Rh30 & RD, in which two different CRIPSR/Cas9 vectors with RASSF5 guide RNA were 
introduced. Then IncuCyte growth assays, western blot and qPCR were performed 
Results: The IncuCyte growth curve for one of the RASSF5 CRISPR Rh30 cell lines, 
Sg1, revealed a faster rate of cell growth compared to the control Rh30s. Also, when 
treated with SGI110 Tx, there is reduction of drug induced growth inhibition of Sg1 Rh30 
cells compared to controls. When looking at the protein level, although Cas9 expression 
was observed, there was no baseline reduction in RASSF5. 
Discussion: While some of this data suggests that we have less activation of the Hippo 
pathway, which would result from a reduction in RASSF5, other data implies that 
RASSF5 was not deleted entirely. Further research is needed to elucidate RASSF5’s 
role in both RMS and the altered Hippo pathway in RMS. 
 
